Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 6.
doi: 10.1007/s41669-025-00603-0. Online ahead of print.

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma

Ellen M Howard  1 , Marc Massetti  2 , Gin Nie Chua  3 , Millie Gaydon  3 , Sara Savar  3 , Andrew Lloyd  3
Affiliations
Free article

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma

Ellen M Howard et al. Pharmacoecon Open. .
Free article

Abstract

Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT. This study aimed to estimate health state utilities for mIDH glioma over the full disease course.

Method: Vignettes were developed to describe states from post-initial resection with no immediate need for RT/CT through to RT/CT and palliative care after recurrence. These were developed on the basis of literature review, patient-reported outcomes data from a clinical trial and qualitative interviews with clinicians and patients. The health state vignettes were valued by members of the UK public using the EQ-5D-5L and time trade-off methods. Subsequently, the vignette-derived utilities were re-weighted with the utility data from a clinical trial to estimate health state utilities for CUA.

Results: Health state utilities were similar following the initial resection for targeted therapy or active observation (0.74) but lower in later stages of disease. Mean utilities for receiving first- and second-line RT/CT ranged from 0.34 to 0.55. Mean utilities ranged from 0.21 to 0.42 for recovery after tumour resection following recurrence and from -0.05 to 0.14 for palliative care.

Conclusion: This study estimates health state utilities in glioma from after the initial resection through to palliative care and suggests that new treatments capable of delaying time to disease recurrence and initiation of RT/CT could produce a net gain in quality of life for individuals with mIDH glioma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: The study was funded by Servier Pharmaceuticals LLC. Conflict of interest: Ellen M. Howard, Gin Nie Chua, Millie Gaydon and Sara Savar are employees of Acaster Lloyd Consulting Ltd. Andrew Lloyd is an employee and shareholder of Acaster Lloyd Consulting Ltd. Acaster Lloyd Consulting Ltd were commissioned by Servier Pharmaceuticals LLC, the study sponsor, to conduct the study. Marc Massetti is an employee of Servier Pharmaceuticals LLC. Authors’ contributions:: Ellen M. Howard: investigation, methodology, formal analysis, project administration, writing—original draft, writing—review and editing and visualisation. Millie Gaydon: investigation, methodology, formal analysis, project administration and writing—original draft. Sara Savar: investigation, methodology, formal analysis, project administration and writing—original draft. Marc Massetti: conceptualisation, methodology and writing—review and editing. Andrew Lloyd: conceptualisation, methodology and writing—review and editing. Gin Nie Chua: conceptualisation, investigation, methodology, formal analysis, project administration, writing—original draft, writing—review and editing, visualisation and validation. Ethics approval: This study was conducted in compliance with the Declaration of Helsinki. Study materials were reviewed and deemed exempt by an institutional review board (Western Institutional Review Board [WIRB], IRB no.: 20241559). Consent to participate: Informed consent was obtained from all participants prior to their involvement in the study. Consent for publication: Informed consent for publication was obtained from all participants prior to their involvement in the study. Data availability: The data that support the findings of this study are not publicly available, as they are proprietary to the study sponsor. Code availability: Not available.

References

    1. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406. - PubMed
    1. Liu Y, Lang F, Chou FJ, Zaghloul KA, Yang C. Isocitrate dehydrogenase mutations in glioma: genetics, biochemistry, and clinical indications. Biomedicines. 2020;8(9):294. - PubMed - PMC - DOI
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. - PubMed - PMC - DOI
    1. Jiang S, Zanazzi GJ, Hassanpour S. Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images. Sci Rep. 2021;11(1):16849. - PubMed - PMC - DOI
    1. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023;25(1):4–25. - PubMed - DOI

LinkOut - more resources